SCHEMBL6030165

SCHEMBL6030165

CCCCCCCCOC(=O)Nc1sc(C(=O)OCCCCCCCC)c(COC)c1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
TSHR P16473 5/20 0.45
MAPT P10636 3/20 0.45
MAPK1 P28482 3/20 0.45
HSD17B10 Q99714 2/20 0.45
CSNK2A2 P19784 2/20 0.41
CSNK2A1 P68400 2/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
EPHX1 P07099 1/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
CASP1 P29466 1/20 0.37
CYP2C9 P11712 1/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6029186 1.00 ALDH1A1 (0.45) ALDH1A1TSHRMAPTMAPK1HSD17B10
SCHEMBL6030310 0.90 TSHR (0.47) ALDH1A1TSHRMAPTMAPK1HSD17B10
SCHEMBL6029188 0.88 ALDH1A1 (0.42) ALDH1A1TSHRMAPTMAPK1HSD17B10
SCHEMBL6030167 0.88 ALDH1A1 (0.42) ALDH1A1TSHRMAPTMAPK1HSD17B10
SCHEMBL6030389 0.80 ALDH1A1 (0.43) ALDH1A1TSHRMAPTMAPK1HSD17B10
SCHEMBL6029907 0.76 PKM (0.47) ALDH1A1TSHRMAPTMAPK1HSD17B10
SCHEMBL6029726 0.76 MAPT (0.48) ALDH1A1TSHRMAPTMAPK1CSNK2A2
SCHEMBL6031318 0.75 PKM (0.48) ALDH1A1TSHRMAPTMAPK1HSD17B10
SCHEMBL6030376 0.73 PKM (0.52) ALDH1A1TSHRMAPTMAPK1HSD17B10
SCHEMBL6030718 0.73 PKM (0.52) ALDH1A1TSHRMAPTMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL ALDH1A1 1832/4885TSHR 212/4885MAPT 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.